Dan Lü

3.7k total citations · 1 hit paper
67 papers, 2.4k citations indexed

About

Dan Lü is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Dan Lü has authored 67 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 20 papers in Immunology and 19 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Dan Lü's work include Monoclonal and Polyclonal Antibodies Research (19 papers), Lymphoma Diagnosis and Treatment (13 papers) and HER2/EGFR in Cancer Research (11 papers). Dan Lü is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (19 papers), Lymphoma Diagnosis and Treatment (13 papers) and HER2/EGFR in Cancer Research (11 papers). Dan Lü collaborates with scholars based in United States, China and France. Dan Lü's co-authors include Ie Ming Shih, Peter Böhlen, Morgan A. Marks, Russell Vang, Anna Yemelyanova, Malti Kshirsagar, Robert J. Kurman, Zhenping Zhu, Xenia Jimenez and Larry Witte and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Dan Lü

66 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis

2011 386 citations Anna Yemelyanova, Russell Vang et al. Modern Pathology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dan Lü United States	25	1.0k	856	396	388	321	67	2.4k
T. Khanh United States	26	1.6k 1.6×	991 1.2×	422 1.1×	238 0.6×	180 0.6×	57	2.5k
Diane L. Persons United States	29	1.4k 1.4×	1.3k 1.5×	412 1.0×	295 0.8×	398 1.2×	64	3.1k
Christoph Bucher Switzerland	13	964 1.0×	882 1.0×	301 0.8×	221 0.6×	363 1.1×	21	2.3k
Coya Tapia Switzerland	28	838 0.8×	1.1k 1.3×	239 0.6×	190 0.5×	253 0.8×	47	2.3k
Paula R. Pohlmann United States	22	655 0.7×	1.3k 1.5×	321 0.8×	335 0.9×	79 0.2×	100	2.3k
Scott Glaser United States	25	986 1.0×	466 0.5×	899 2.3×	242 0.6×	128 0.4×	145	2.5k
Thierry Petit France	24	542 0.5×	1.3k 1.6×	270 0.7×	143 0.4×	175 0.5×	133	2.2k
Tiziana Camerini Italy	27	1.2k 1.2×	1.2k 1.4×	295 0.7×	306 0.8×	198 0.6×	39	3.5k
Sarah P. Blagden United Kingdom	34	1.8k 1.8×	1.1k 1.3×	113 0.3×	195 0.5×	168 0.5×	154	3.2k
Riccardo Giannini Italy	34	1.6k 1.6×	1.4k 1.7×	175 0.4×	272 0.7×	624 1.9×	104	4.6k

Countries citing papers authored by Dan Lü

Since Specialization

Citations

This map shows the geographic impact of Dan Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Lü more than expected).

Fields of papers citing papers by Dan Lü

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Lü. The network helps show where Dan Lü may publish in the future.

Co-authorship network of co-authors of Dan Lü

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Lü. A scholar is included among the top collaborators of Dan Lü based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Lü. Dan Lü is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Gengbo, et al.. (2024). Deep‐NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data. CPT Pharmacometrics & Systems Pharmacology. 13(5). 870–879. 2 indexed citations

Dere, Randall, Richard L. Beardsley, Dan Lü, et al.. (2023). Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Frontiers in Immunology. 14. 1119510–1119510. 4 indexed citations

Wang, Pengyan, Can Yue, Kefang Liu, et al.. (2021). Peptide Presentations of Marsupial MHC Class I Visualize Immune Features of Lower Mammals Paralleled with Bats. The Journal of Immunology. 207(8). 2167–2178. 5 indexed citations

Depetris, Rafael S., Dan Lü, Zhikai Zhang, et al.. (2021). Functional antibody characterization via direct structural analysis and information‐driven protein–protein docking. Proteins Structure Function and Bioinformatics. 90(4). 919–935. 5 indexed citations

Martomo, Stella, et al.. (2020). Single-Dose Anti–PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses. Molecular Cancer Therapeutics. 20(2). 347–356. 22 indexed citations

Shemesh, Colby S., Priya Agarwal, Tong Lu, et al.. (2020). Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology. 85(5). 831–842. 11 indexed citations

Lü, Dan, Tong Lu, Leonid Gibiansky, et al.. (2020). Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma. Pharmaceutical Research. 37(12). 252–252. 13 indexed citations

Lü, Dan, Kefang Liu, Di Zhang, et al.. (2019). Peptide presentation by bat MHC class I provides new insight into the antiviral immunity of bats. PLoS Biology. 17(9). e3000436–e3000436. 25 indexed citations

Liu, Kefang, Yan Chai, Dan Lü, et al.. (2019). Divergent Peptide Presentations of HLA-A*30 Alleles Revealed by Structures With Pathogen Peptides. Frontiers in Immunology. 10. 1709–1709. 14 indexed citations

10.

Tilly, Hervé, Franck Morschhauser, Nancy L. Bartlett, et al.. (2019). Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. The Lancet Oncology. 20(7). 998–1010. 93 indexed citations

11.

Zhu, Rui, Dan Lü, Yu‐Waye Chu, et al.. (2017). Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies. The AAPS Journal. 19(3). 669–681. 11 indexed citations

12.

Advani, Ranjana H., Daniel Lebovic, Andy Chen, et al.. (2016). Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research. 23(5). 1167–1176. 65 indexed citations

13.

Yemelyanova, Anna, Russell Vang, Malti Kshirsagar, et al.. (2011). Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Modern Pathology. 24(9). 1248–1253. 386 indexed citations breakdown →

14.

Xu, Xianxiang, Xinghua Gao, Rong Pan, Dan Lü, & Yue Dai. (2010). A simple adhesion assay for studying interactions between platelets and endothelial cells in vitro. Cytotechnology. 62(1). 17–22. 13 indexed citations

15.

Lü, Dan, Chien‐Fu Hung, Shiwen Peng, et al.. (2007). Ectopic Expression of Vascular Cell Adhesion Molecule-1 as a New Mechanism for Tumor Immune Evasion. Cancer Research. 67(4). 1832–1841. 71 indexed citations

16.

Lü, Dan, Juqun Shen, Haifan Zhang, et al.. (2003). Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity. Journal of Biological Chemistry. 278(44). 43496–43507. 156 indexed citations

17.

Drum, Chester Lee, Shui-Zhong Yan, Joel Bard, et al.. (2002). Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature. 415(6870). 396–402. 317 indexed citations

18.

Lü, Dan, Paul Kussie, Bronislaw Pytowski, et al.. (2000). Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies. Journal of Biological Chemistry. 275(19). 14321–14330. 59 indexed citations

19.

Leitenberg, David, Yvan Boutin, Dan Lü, & Kim Bottomly. (1999). Biochemical Association of CD45 with the T Cell Receptor Complex. Immunity. 10(6). 701–711. 61 indexed citations

20.

Lü, Dan, Helen Kotanides, Xenia Jimenez, et al.. (1999). Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. Journal of Immunological Methods. 230(1-2). 159–171. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact